Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 260-269

  Bozdaǧ, Sibel ^a   Gümüş, Koray ^b   Gümüş, Özlem ^a   Ünlü, Nurşen ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Corneal cystinosis; Cysteamine hydrochloride; HPMC viscous solutions; In vitro characterization; Stability

Indexed keywords

BENZALKONIUM; CARBOPOL 940; CARBOPOL 980; EDETATE DISODIUM; EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; MERCAPTAMINE; SODIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOCLAVE; CONTROLLED STUDY; CORNEAL CYSTINOSIS; CYSTINOSIS; DRUG FORMULATION; DRUG STABILITY; EVALUATION; EYE IRRITATION; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INSTRUMENT STERILIZATION; MALE; NONHUMAN; NORMAL HUMAN; OSMOLALITY; PH; RABBIT; STORAGE TEMPERATURE; TECHNIQUE; VISCOSITY;

ACUTE TOXICITY TESTS; ADMINISTRATION, TOPICAL; ADULT; ANIMALS; BENZALKONIUM COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CORNEAL DISEASES; CYSTEAMINE; CYSTINOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG STABILITY; EXCIPIENTS; EYE; FEMALE; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MALE; METHYLCELLULOSE; OPHTHALMIC SOLUTIONS; ORPHAN DRUG PRODUCTION; OSMOLAR CONCENTRATION; PRESERVATIVES, PHARMACEUTICAL; RABBITS; SOLUBILITY; STERILIZATION; VISCOSITY;

EID: 50149104737     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.010     Document Type: Article

References (45)

1. Iwata F., Kuehl E.M., Reed G.F., McCain L.M., Gahl W.A., and Kaiser-Kupfer M.I. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol. Genet. Metab. 64 (1998) 237-242
2. Gahl F.W.A., Thoene J.G., and Schneider J.A. Cystinosis. N. Eng. J. Med. 347 (2002) 111-121
3. Gahl W.A., Bashan N., Tietze F., Bernardini I., and Schulman J.D. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217 (1982) 1263-1265
4. Town M., Jean G., Cherqui S., Attard M., Forestier L., Whitmore S.A., Callen D.F., Gribouval O., Broyer M., Bates G.P., van't Hoff W., and Antignac C. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat. Genet. 18 (1998) 319-324
5. Tsilou E.T., Thompson D., Lindblad A.S., Reed G.F., Rubin B., Gahl W., Thoene J., Del Monte M., Schneider J.A., Granet D.B., and Kaiser-Kupfer M.I. A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br. J. Ophthalmol. 87 (2003) 28-31
6. Gahl W.A., Reed G.F., Thoene J.G., Schulman J.D., Rizzo W.B., Jonas A.J., Denman D.W., Schlesselman J.J., Corden B.J., and Schneider J.A. Cysteamine therapy for children with nephropathic cystinosis. N. Engl. J. Med. 316 (1987) 971-977
7. Gahl W.A., Kuehl E.M., Iwata F., Lindblad A., and Kaiser-Kupfer M.I. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol. Genet. Metab. 71 (2000) 100-120
8. Tenneze L., Daurat V., Tibi A., Chaumet-Riffaud P., and Funck-Brentano C. A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. Br. J. Clin. Pharmacol. 47 (1999) 49-52
9. MacDonald I.M., Noel L.P., Mintsioulis G., and Clarke W.N. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J. Pediatr. Ophthalmol. Strabismus 27 (1990) 272-274
10. Kaiser-Kupfer M.I., Gazzo M.A., Datiles M.B., Caruso R.C., Kuehl E.M., and Gahl W.A. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch. Ophthalmol. 108 (1990) 689-693
11. Kaiser-Kupfer M.I., Fujikawa L., Kuwabara T., Jain S., and Gahl W.A. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N. Engl. J. Med. 316 (1987) 775-779
12. Tsilou E.T., Rubin B., Reed G., Caruso R., Iwata F., Balog J., Gahl W., and Kaiser-Kupfer M. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy. Ophthalmology 113 (2006) 1002-1009
13. Dureau P., Broyer M., and Dufier J.L. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine. J. Pediatr. Ophthalmol. Strabismus 40 (2003) 142-146
14. Markello T.C., Bernardini I.M., and Gahl W.A. Improved renal function in children with cystinosis treated with cysteamine. N. Engl. J. Med. 328 (1993) 1157-1162
15. Kimonis V.E., Troendle J., Rose S.R., Yang M.L., Markello T.C., and Gahl W.A. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J. Clin. Endocrinol. Metab. 80 (1995) 3257-3261
16. Thoene J.G., Oshima R.G., Crawhall J.C., Olson D.L., and Schneider J.A. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J. Clin. Invest. 58 1 (1976) 180-189
17. U.S. Cysteamine Eye Drop Development, Sigma Tau Pharmaceutical, 2004. Available from: http://www.cystinosis.com/Documents/EyeDropPaper.html.
18. Jones N.P., Postlethwaite R.J., and Noble J.L. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%. Br. J. Ophthalmol. 75 (1991) 311-312
19. Wade A., and Weller P.J. Handbook of Pharmaceutical Excipients. second ed. (1994), Pharmaceutical Press, London
20. The United States Pharmacopoeia, 27th ed., US Pharmacopoeial Inc., Webcom Limited, Toronto, Canada, 2004.
21. Kast C.E., and Bernkop-Schnurch A. Polymer-cysteamine conjugates: new mucoadhesive excipients for drug delivery?. Int. J. Pharm. 234 (2002) 91-99
22. Bernkop-Schnürch A., Scholler S., and Biebel R.G. Development of controlled release systems based on thiolated polymers. J. Control. Release 66 (2000) 39-48
23. Chanakira A., Chikwana E., Peyton D.H., and Simoyi R.H. Oxyhalogen-sulfur chemistry-kinetics and mechanism of the oxidation of cysteamine by acidic iodate and iodine. Can. J. Chem. 84 (2006) 49-57
24. Material Safety Data Sheet, Iodometric titration of 2-mercaptoethylamine hydrochloride (M6500), Sigma, 2006.
25. Cavallini D., Scandurra R., and De Marco C. The role of sulphur, sulphide and reducible dyes in the enzymic oxidation of cysteamine to hypotaurine. Biochem. J. 96 (1965) 781-786
26. Nasiredeen S., Kas H.S., Öner F., and Hi{dotless}ncal A.A. Parenteral emulsions as drug carriers: formulation and stability evaluation. J. Control. Release 48 (1997) 289-363
27. Nounou M.M., El-Khordagui L.K., Khalafallah N.A., and Khalil S.A. In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels. Acta Pharm. 56 (2006) 311-324
28. Van Haeringen N.J. Clinical biochemistry of tears. Surv. Ophthalmol. 5 (1981) 84-96
29. Giannavola C., Bucolo C., Maltese A., Paolino D., Vandelli M.A., Puglisi G., Lee V.H.L., and Fresta M. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of peg coating on ocular drug bioavailability. Pharm. Res. 20 (2003) 584-590
30. Greaves J.L., Olejnik O., and Wilson C.G. Polymers and the precorneal tear film. S.T.P. Pharm. Sci. 2 (1992) 13-33
31. Toda I., Shinozaki N., and Tsubota K. Hydroxypropyl methylcellulose for the treatment of severe dry eye associated with Sjogren's syndrome. Cornea 15 (1996) 120-128
32. Ray-Chaudhuri N., Voros G.M., Sutherland S., and Figueiredo F.C. Comparison of the effect of sodium hyaluronate (Ophthalin) and hydroxypropylmethylcellulose (HPMC-Ophtal) on corneal endothelium, central corneal thickness, and intraocular pressure after phacoemulsification. Eur. J. Ophthalmol. 16 (2006) 239-246
33. de Silva D.J., and Olver J.M. Hydroxypropyl methylcellulose (HPMC) lubricant facilitates insertion of porous spherical orbital implants. Ophthal. Plast. Reconstr. Surg. 21 (2005) 301-302
34. Liu Z., Li J., Nie S., Liu H., Ding P., and Pan W. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int. J. Pharm. 315 (2006) 12-17
35. Greaves J.L., Wilson C.G., and Birmingham A.T. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects. Br. J. Clin. Pharmacol. 35 (1993) 188-192
36. European Pharmacopoeia, fourth edition, Council of Europe, Strasbourg, France, 1997.
37. Chen H.H. Rheological properties of HPMC enhanced Surimi analyzed by small- and largr-strain tests: I. The effect of concentration and temperature on HPMC flow properties. Food Hydrocolloids 21 (2007) 1201-1208
38. Kulicke W.M., Arendt O., and Berger M. Rheological characterization of the dilatant flow behavior of highly substituted hydroxypropylmethyl-cellulose solutions in the presence of sodium lauryl sulfate. Colloid Polym. Sci. 276 (2004) 617-626
39. Ludwig A., Van Ooteghem M., Van Haeringen N.J., and Bodelier V.M.W. Relationship between precorneal retention of viscous eye drops and tear fluid composition. J. Int. Ophthalmol. 16 (1992) 23-26
40. Tomoaki H., and Ford J.L. Effect of nicotinamide on the properties of aqueous HPMC solutions. Int. J. Pharm. 226 (2001) 53-60
41. Reddy M.S., Mutalik S., and Rao G.V. Preparation and evaluation of minoxidil gels for topical application in alopecia. Indian J. Pharm. Sci. 68 (2006) 432-436
42. Srividya B., Cardoza R.M., and Amin P.D. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J. Control. Release 73 (2001) 205-211
43. Bourges X., Weiss P., Daculsi G., and Legeay G. Synthesis and general properties of silated-hydroxypropyl methylcellulose in prospect of biomedical use. Adv. Colloid Interface Sci. 99 (2002) 215-228
44. Duggirala S., and DeLuca P.P. Rheological characterization of cellulosic and alginate polymers. PDA J. Pharm. Sci. Technol. 50 (1996) 290-296
45. Bohic S., Weiss P., Roger P., and Daculsi G. Light scattering experiments on aqueous solutions of selected cellulose ethers: contribution to the study of polymer-mineral interactions in a new injectable biomaterial. J. Mater. Sci. Mater. Med. 12 (2001) 201-205